Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China

OBJECTIVE: The objective of this study is to evaluate the cost-effectiveness of adding pembrolizumab to the standard first-line therapy of advanced biliary tract cancer (BTC) with gemcitabine and cisplatin from the perspective of the Chinese healthcare system. METHODS: The partitioned survival model...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Zhiwei, Fang, Ling, Cai, Hongfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476407/
https://www.ncbi.nlm.nih.gov/pubmed/37667230
http://dx.doi.org/10.1186/s12885-023-11255-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476407/
https://www.ncbi.nlm.nih.gov/pubmed/37667230
http://dx.doi.org/10.1186/s12885-023-11255-w

Ejemplares similares